Cellesce has successfully raised funds which will be used to complete the development of an innovative process for the expansion of organoids.

Organoid models are a powerful new enabling technology in cancer drug discovery. Because organoids are closer to in vivo tissue structure than other available models, they give more accurate responses to drug candidates. Using organoids in drug discovery assays, pharmaceutical companies can pick ‘winners’ earlier and weed out ‘losers’ before incurring high development costs.


We are pleased to welcome four non-executive directors to the board. John Allbrook will join as the board as Chairman. Francis Bealin Kelly, Mark Cole and Chris Thompson bring a wealth of experience in building and running new technology businesses.